AXON - Axovant Sciences Ltd.
| Previous Close | 1.92 |
| Open | 1.92 |
| Bid | 1.86 x 2200 |
| Ask | 2.02 x 1200 |
| Day's Range | 1.90 - 2.01 |
| 52 Week Range | 1.02 - 6.59 |
| Volume | 516,809 |
| Avg. Volume | 712,820 |
| Market Cap | 244.162M |
| Beta (3Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.52 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.70 |
- Associated Press•10 days ago
Axovant: Fiscal 2Q Earnings Snapshot
The London-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- GlobeNewswire•10 days ago
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s diseaseExpanded pipeline of gene therapies with in-licensing of.
- MarketWatch•18 days ago
Axonics prices IPO at $15 a share
Axonics Modulation Technologies Inc. priced its initial public offering at $15 a share, the midpoint of its $14 to $16 price range. The medical technology company, which specializes in sacral neuromodulation treatments for overactive bladder and urinary retention among other disorders, sold 8 million shares to raise $120 million. The stock will start trading later Wednesday on Nasdaq under the ticker symbol "AXNX". BofA Merrill Lynch and Morgan Stanley were joint bookrunning mangers on the deal with Wells Fargo acting as lead manager and SunTrust Robinson Humphrey acting as co-manager.
- GlobeNewswire•24 days ago
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
Axovant Sciences (AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in a clinical study of AXO-Lenti-PD (also known as OXB-102), an investigational gene therapy for the treatment of Parkinson’s disease. AXO-Lenti-PD is a novel gene therapy that enables the expression of a set of three critical enzymes required for end-to-end dopamine synthesis in the brain. AXO-Lenti-PD was administered to the first patient in the study at the Clinical Research Facility affiliated with the National Institute for Health Research (NIHR) and University College London Hospitals (UCLH).
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
Investors need to pay close attention to Axovant Sciences (AXON) stock based on the movements in the options market lately.
- GlobeNewswire•last month
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
BASEL, Switzerland, Oct. 09, 2018 -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular.
Markit•2 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•2 months ago
Axovant to Present at Two Upcoming Investor Conferences
BASEL, Switzerland, Sept. 20, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September ...
- PR Newswire•2 months ago
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
BASEL, Switzerland and SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD.
- Market Realist•2 months ago
What Spark Therapeutics’ Valuation Trend Indicates
Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.
Market Realist•2 months agoInvestors Still Excited about Axovant
Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapies in neurology and psychiatry. Its product candidates are targeted at neurological diseases, including Parkinson’s disease, oculopharyngeal muscular dystrophy, Lewy body dementia, and other indications. The former is a potential one-time treatment for Parkinson’s disease, and the latter is a potential one-time treatment for oculopharyngeal muscular dystrophy.
Market Realist•2 months agoAnalyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.
Market Realist•2 months agoAudentes Therapeutics’ Promising Product Pipeline
Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•3 months ago
Axovant to Present at Upcoming Investor Conferences
BASEL, Switzerland, Aug. 29, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- ACCESSWIRE•3 months ago
Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo
NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Gevo and Axovant Sciences had something in common on Tuesday. Axovant Sciences Ltd. was up 14.43% at the close on Tuesday on about 1.5 million shares traded.
Markit•3 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Market Realist•3 months agoPuma Biotechnology: Recent Developments and Recommendations
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
- Associated Press•3 months ago
Axovant: Fiscal 1Q Earnings Snapshot
On a per-share basis, the London-based company said it had a loss of 48 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $22.89. _____ ...
Markit•4 months agoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Zacks•4 months ago
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•4 months ago
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
